ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: The Company develops, manufactures, and markets disposable medical devices, primarily connection systems for intravenous (I.V.) therapy (CLAVE) and custom I.V. systems. A significant portion of revenue is derived from a Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira, Inc., under which ICU Medical manufactures critical care products exclusively for Hospira.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 7.5% for the nine months ended September 30, 2007, compared to the prior year. This was primarily due to the discontinuation of certain products under the MCDA and the termination of the Punctur Guard product line in early 2007. Excluding discontinued products, revenue increased 5%.
• Customer Concentration: Hospira, Inc. remains the dominant customer, accounting for 73% of total revenue for the nine months ended September 30, 2007 (down from 77% in the prior year).
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to 25% of revenue (from 23% in 2006) due to higher compensation and marketing costs, partially offset by a significant decrease in legal expenses following the conclusion of two major legal actions.
• Other Income: Other income increased significantly to $7.4 million for the nine months ended September 30, 2007 (from $3.2 million in 2006). This includes an $8.0 million legal settlement gain, partially offset by a $4.8 million charge for legal fees awarded to Alaris Medical Systems in a patent dispute.
• Capital Expenditures: Investing activities used $14.3 million, driven by $19.1 million in property and equipment purchases, primarily for the expansion of the Mexico facility.

Guidance, Outlook, and Risks

• Margin Outlook: Management estimates gross margins will approach 45% by December 2007, following production inefficiencies in late 2006 that have since improved.
• Expense Outlook: SG&A is expected to approximate 24% of revenue for the full year 2007. R&D is expected to be 4-5% of revenue.
• Capital Allocation: The Company announced a new stock repurchase program in September 2007 to buy up to an additional $20.0 million of common stock. Total capital expenditures for 2007 are estimated at $23.0 million.
• Key Risks:
  • Customer Dependence: Continued reliance on Hospira for 73% of revenue creates significant risk if the relationship deteriorates or Hospira's market position declines.
  • Market Decline: The U.S. market for critical care products is declining, which is expected to further reduce sales under the MCDA in 2008 and 2009.
  • Litigation: The Company is appealing a $4.8 million judgment against it regarding legal fees in a patent dispute with Alaris Medical Systems. The outcome remains uncertain.
  • Competition: Potential price erosion and competition in the CLAVE product line if patent enforcement is unsuccessful.

Investor Verification Checklist

• Verify the status and potential financial impact of the pending appeal regarding the $4.8 million Alaris Medical Systems judgment.
• Monitor the trend of sales to Hospira, specifically the decline in critical care products versus growth in custom I.V. systems.
• Assess the progress of the Mexico facility expansion and its impact on achieving the projected 45% gross margin target.
• Review the execution of the new $20.0 million stock repurchase program and its effect on share count.
• Confirm the stability of the MCDA pricing structure and the potential for further price reductions in 2008-2009.